Investor Presentaiton

SELECT TRIALS - TIRZEPATIDE (CONT.) Lilly Primary Completion Completion Study Indication* Title Phase Patients Primary Outcome* ** NCT04166773 Steatohepatitis Nonalcoholic A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (SYNERGY-NASH) 2 196 Percentage of Participants with Absence of NASH with no Worsening of Fibrosis on Liver Histology Jan 2024 Feb 2024 NCT05412004 Sleep Apnea Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (SURMOUNT-OSA) 3 469 Percent Change from Baseline in Apnea-Hypopnea Index (AHI) Mar 2024 Mar 2024 A Study of Tirzepatide (LY3298176) in Participants With NCT04847557 HFpEF Heart Failure With Preserved Ejection Fraction and Obesity 3 700 (SUMMIT) NCT05536804 CKD A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or 2 Without Type 2 Diabetes (TREASURE-CKD) 140 A Hierarchical Composite of All-Cause Mortality, Heart Failure Events, 6-minute Walk Test Distance (6MWD) and Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) Category Jun 2024 Jul 2024 Change from Baseline in Kidney Oxygenation in Participants With or Without T2D [ Time Frame: Baseline, Week 52 ]; Blood oxygenation-level dependent magnetic resonance imaging (BOLD MRI) Oct 2025 Nov 2025 * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use Source: clinicaltrials.gov, July 25, 2023 2023 Q2 EARNINGS 49

View entire presentation